Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Guardant Health reported its second quarter 2026 financial results highlighting broad-based growth across all key segments: Oncology, Biopharma & Data, and Screening.</li><li>Total revenue reached $335 million, up 44% year-over-year, with Oncology revenue at $219 million (38% growth), Biopharma & Data at $61 million (9% growth), and Screening revenue rising significantly to $53 million from $15 million a year ago.</li><li>The company demonstrated accelerated test volume growth, particularly in its Oncology business, where volumes increased 63% year-over-year to approximately 104,000 tests, supported by expansions in products such as Guardant360 Liquid (over 30% volume growth), Guardant360 Tissue, and Reveal, the latter growing over 100% driven by minimal residual disease (MRD) and therapy monitoring adoption.</li></ul>

Guardant Health reported its second quarter 2026 financial results highlighting broad-based growth across all key segments: Oncology, Biopharma & Data, and Screening.Total revenue reached $335 million, up 44% year-over-year, with Oncology revenue at $219 million (38% growth), Biopharma & Data at $61 million (9% growth), and Screening revenue rising significantly to $53 million from $15 million a year ago.The company demonstrated accelerated test volume growth, particularly in its Oncology business, where volumes increased 63% year-over-year to approximately 104,000 tests, supported by expansions in products such as Guardant360 Liquid (over 30% volume growth), Guardant360 Tissue, and Reveal, the latter growing over 100% driven by minimal residual disease (MRD) and therapy monitoring adoption.

Guardant Health’s 70 Million-Patient Breakthrough — Shield Is Scaling Fast!

<ul><li>Guardant Health reported a strong first quarter for 2026, highlighted by robust revenue growth across its key business segments: Oncology, Biopharma & Data, and Screening.</li><li>Total revenue reached $302 million, a 48% increase year-over-year, marking the fastest annual growth rate for the company in five years and surpassing a trailing 12-month revenue milestone of $1 billion.</li><li>This growth was attributed to increasing test volumes and broad-based adoption of its diagnostic products.</li></ul>

Guardant Health reported a strong first quarter for 2026, highlighted by robust revenue growth across its key business segments: Oncology, Biopharma & Data, and Screening.Total revenue reached $302 million, a 48% increase year-over-year, marking the fastest annual growth rate for the company in five years and surpassing a trailing 12-month revenue milestone of $1 billion.This growth was attributed to increasing test volumes and broad-based adoption of its diagnostic products.

Guardant Health Tops $1 Billion TTM Revenue As Test Volumes Surge!

<ul><li>Guardant Health has entered 2026 with accelerating revenue growth, expanding gross margins, and a sharpened strategic focus across oncology and cancer screening.</li><li>Fresh off a 39% year-over-year revenue surge in the fourth quarter of 2025 and full-year revenue approaching $1 billion, the company is now layering in inorganic innovation to deepen its competitive moat.</li><li>In December, Guardant completed the acquisition of Israel-based MetaSight Diagnostics for $59 million upfront, with up to $90 million in milestone payments tied to regulatory and commercial achievements.</li></ul>

Guardant Health has entered 2026 with accelerating revenue growth, expanding gross margins, and a sharpened strategic focus across oncology and cancer screening.Fresh off a 39% year-over-year revenue surge in the fourth quarter of 2025 and full-year revenue approaching $1 billion, the company is now layering in inorganic innovation to deepen its competitive moat.In December, Guardant completed the acquisition of Israel-based MetaSight Diagnostics for $59 million upfront, with up to $90 million in milestone payments tied to regulatory and commercial achievements.

Guardant Health Is Expanding Beyond Oncology—And MetaSight Is The Key!

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM). </li>
<li>Additionally, we continue to believe the bottom is in for SPX, IWM, QQQ, and Technology areas (XLK, IGV, SOXX, CHAT).</li>
<li>With that said, some mixed price action in A.I. themes -- notably semiconductors (SOXX), generative A.I. (CHAT), memory (DRAM), and neoclouds (WGMI) -- are giving us some reason for pause.</li>
</ul>


We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM). 
Additionally, we continue to believe the bottom is in for SPX, IWM, QQQ, and Technology areas (XLK, IGV, SOXX, CHAT).
With that said, some mixed price action in A.I. themes -- notably semiconductors (SOXX), generative A.I. (CHAT), memory (DRAM), and neoclouds (WGMI) -- are giving us some reason for pause.


Mixed Signals in A.I. Names (SOXX, CHAT, DRAM, WGMI); Bullish Outlook Intact

<ul>
<li>Since late-February (2/25/25 Compass) we expected an 8-10% pullback to provide a buying opportunity. But that all changed in last week's Compass (4/1/25), when we downgraded our outlook to bearish/cautious.</li>
<li>A historic selloff has ensued and significant damage has been done as market dynamics have worsened.</li>
<li>Until we see some base-building process develop alongside improving market dynamics, we remain cautious and we continue to favor defensives as long as the SPX is below its 200-day MA.</li>
</ul>


Since late-February (2/25/25 Compass) we expected an 8-10% pullback to provide a buying opportunity. But that all changed in last week's Compass (4/1/25), when we downgraded our outlook to bearish/cautious.
A historic selloff has ensued and significant damage has been done as market dynamics have worsened.
Until we see some base-building process develop alongside improving market dynamics, we remain cautious and we continue to favor defensives as long as the SPX is below its 200-day MA.


S&P 500 and Nasdaq 100 Testing Prior 2022 Highs; Still Bearish and Cautious

United States

Guardant Health, Inc. operates as a biotechnology company. The Company provides sequencing and cell diagnostics services for the cancer patients. Guardant Health serves patients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Guardant Health (GH US)

Guardant Health’s 70 Million-Patient Breakthrough — Shield Is Scaling Fast!

Guardant Health reported its second quarter 2026 financial results highlighting broad-based growth across all key segments: Oncology, Biopharma...

Baptista Research

Guardant Health Tops $1 Billion TTM Revenue As Test Volumes Surge!

Guardant Health reported a strong first quarter for 2026, highlighted by robust revenue growth across its key business segments: Oncology,...

Baptista Research

Guardant Health Is Expanding Beyond Oncology—And MetaSight Is The Key!

Guardant Health has entered 2026 with accelerating revenue growth, expanding gross margins, and a sharpened strategic focus across oncology and...

Baptista Research

Mixed Signals in A.I. Names (SOXX, CHAT, DRAM, WGMI); Bullish Outlook Intact

Mixed Signals in A.I. Names ($SOXX $CHAT $DRAM $WGMI); Bullish Outlook Intact $SPX $QQQ $IWM. $CHAT breaking above the 50-day MA likely signaling...

Vermilion Research

S&P 500 and Nasdaq 100 Testing Prior 2022 Highs; Still Bearish and Cautious

$SPX and Nasdaq 100 $QQQ Testing Prior 2022 Highs; Upgrading Health Care $XLV; Downgrading Transportation $IYT; Still Bearish and Cautious; Sell...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)